Biomarkers for colorectal cancer

International Journal of Molecular Sciences

Volumn 11, Issue 9, 2010, Pages 3209-3225

  Tanaka, Takuji ^a,b   Tanaka, Mayu ^c   Tanaka, Takahiro ^d   Ishigamori, Rikako ^e  

^a Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c KINJO GAKUIN UNIVERSITY   (Japan)

^d KANSAI UNIVERSITY OF HEALTH SCIENCES   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Biomarkers; Colorectal cancer; Fecal biomarkers; Genomic and epigenetic biomarkers; MicroRNA; Serum biomarkers

Indexed keywords

ALPHA 1 ANTITRYPSIN; APC PROTEIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; COLONY STIMULATING FACTOR 1; DEATH RECEPTOR 5; DNA; GELATINASE B; HEMOGLOBIN; K RAS PROTEIN; LAMININ; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; MICRORNA; NICOTINAMIDE METHYLTRANSFERASE; PROLACTIN; PROTEASOME ACTIVATOR COMPLEX 3; PROTEIN P53; PYRUVATE KINASE; SEPTIN; SPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFERRIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; EARLY DIAGNOSIS; EPIGENETICS; FECES ANALYSIS; GENETIC MARKER; GENOMICS; HUMAN; MEDICAL EXAMINATION; MICROSATELLITE INSTABILITY; NON INVASIVE MEASUREMENT; OCCULT BLOOD TEST; PROTEOMICS; REVIEW; VALIDATION STUDY;

BIOMARKERS; COLORECTAL CANCER; FECAL BIOMARKERS; GENOMIC AND EPIGENETIC BIOMARKERS; MICRORNA; SERUM BIOMARKERS;

COLORECTAL NEOPLASMS; HUMANS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 77958502935     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11093209     Document Type: Review

References (93)

1. Bingham, S.; Riboli, E. Diet and cancer-the european prospective investigation into cancer and nutrition. Nat. Rev. Cancer 2004, 4, 206-215.
2. Sung, J.J.; Lau, J.Y.; Goh, K.L.; Leung, W.K. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol. 2005, 6, 871-876.
3. Hardcastle, J.D.; Chamberlain, J.O.; Robinson, M.H.; Moss, S.M.; Amar, S.S.; Balfour, T.W.; James, P.D.; Mangham, C.M. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348, 1472-1477.
4. Kronborg, O.; Fenger, C.; Olsen, J.; Jorgensen, O.D.; Sondergaard, O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348, 1467-1471.
5. Winawer, S.; Fletcher, R.; Rex, D.; Bond, J.; Burt, R.; Ferrucci, J.; Ganiats, T.; Levin, T.; Woolf, S.; Johnson, D.; Kirk, L.; Litin, S.; Simmang, C. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003, 124, 544-560.
6. Booth, R.A. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007, 249, 87-96.
7. Habermann, J.K.; Bader, F.G.; Franke, C.; Zimmermann, K.; Gemoll, T.; Fritzsche, B.; Ried, T.; Auer, G.; Bruch, H.P.; Roblick, U.J. From the genome to the proteome-biomarkers in colorectal cancer. Langenbecks Arch. Surg. 2008, 393, 93-104.
8. Kim, S.Y.; Hahn, W.C. Cancer genomics: Integrating form and function. Carcinogenesis 2007, 28, 1387-1392.
9. Duffy, M.J.; van Dalen, A.; Haglund, C.; Hansson, L.; Holinski-Feder, E.; Klapdor, R.; Lamerz, R.; Peltomaki, P.; Sturgeon, C.; Topolcan, O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 2007, 43, 1348-1360.
10. Huang, C.S.; Lal, S.K.; Farraye, F.A. Colorectal cancer screening in average risk individuals. Cancer Causes Control 2005, 16, 171-188.
11. Mandel, J.S.; Bond, J.H.; Church, T.R.; Snover, D.C.; Bradley, G.M.; Schuman, L.M.; Ederer, F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N. Engl. J. Med. 1993, 328, 1365-1371.
12. Loktionov, A.; O'Neill, I.K.; Silvester, K.R.; Cummings, J.H.; Middleton, S.J.; Miller, R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin. Cancer Res. 1998, 4, 337-342.
13. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441, 424-430.
14. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
15. Losi, L.; Roncucci, L.; di Gregorio, C.; de Leon, M.P.; Benhattar, J. K-ras and p53 mutations in human colorectal aberrant crypt foci. J. Pathol. 1996, 178, 259-263.
16. Shivapurkar, N.; Huang, L.; Ruggeri, B.; Swalsky, P.A.; Bakker, A.; Finkelstein, S.; Frost, A.; Silverberg, S. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett. 1997, 115, 39-46.
17. Smith, A.J.; Stern, H.S.; Penner, M.; Hay, K.; Mitri, A.; Bapat, B.V.; Gallinger, S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994, 54, 5527-5530.
18. Takahashi, M.; Wakabayashi, K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004, 95, 475-480.
19. Mills, A.A. p53: Link to the past, bridge to the future. Genes Dev. 2005, 19, 2091-2099.
20. Iacopetta, B. TP53 mutation in colorectal cancer. Hum. Mutat. 2003, 21, 271-276.
21. Hart, M.J.; de los Santos, R.; Albert, I.N.; Rubinfeld, B.; Polakis, P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr. Biol. 1998, 8, 573-581.
22. Ahlquist, D.A.; Skoletsky, J.E.; Boynton, K.A.; Harrington, J.J.; Mahoney, D.W.; Pierceall, W.E.; Thibodeau, S.N.; Shuber, A.P. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000, 119, 1219-1227.
23. Srivastava, S.; Verma, M.; Henson, D.E. Biomarkers for early detection of colon cancer. Clin. Cancer Res. 2001, 7, 1118-1126.
24. Dietmaier, W.; Wallinger, S.; Bocker, T.; Kullmann, F.; Fishel, R.; Ruschoff, J. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression. Cancer Res. 1997, 57, 4749-4756.
25. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J.; Goldberg, R.M.; Hamilton, S.R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E.; Tu, D.; Redston, M.; Gallinger, S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349, 247-257.
26. Esteller, M.; Levine, R.; Baylin, S.B.; Ellenson, L.H.; Herman, J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17, 2413-2417.
27. Albaugh, G.P.; Iyengar, V.; Lohani, A.; Malayeri, M.; Bala, S.; Nair, P.P. Isolation of exfoliated colonic epithelial cells, a novel, non-invasive approach to the study of cellular markers. Int. J. Cancer 1992, 52, 347-350.
28. Boynton, K.A.; Summerhayes, I.C.; Ahlquist, D.A.; Shuber, A.P. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin. Chem. 2003, 49, 1058-1065.
29. Imperiale, T.F.; Ransohoff, D.F.; Itzkowitz, S.H.; Turnbull, B.A.; Ross, M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 2004, 351, 2704-2714.
30. Soreide, K.; Nedrebo, B.S.; Knapp, J.C.; Glomsaker, T.B.; Soreide, J.A.; Korner, H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surg. Oncol. 2009, 18, 31-50.
31. Duffy, M.J. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin. Chem. 2001, 47, 624-630.
32. Magnani, J.L.; Nilsson, B.; Brockhaus, M.; Zopf, D.; Steplewski, Z.; Koprowski, H.; Ginsburg, V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 1982, 257, 14365-14369.
33. Duffy, M.J. CA 19-9 as a marker for gastrointestinal cancers: A review. Ann. Clin. Biochem. 1998, 35, 364-370.
34. Hundt, S.; Haug, U.; Brenner, H. Blood markers for early detection of colorectal cancer: A systematic review. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1935-1953.
35. Holten-Andersen, M.N.; Murphy, G.; Nielsen, H.J.; Pedersen, A.N.; Christensen, I.J.; Hoyer-Hansen, G.; Brunner, N.; Stephens, R.W. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br. J. Cancer 1999, 80, 495-503.
36. Sorensen, N.M.; Schrohl, A.S.; Jensen, V.; Christensen, I.J.; Nielsen, H.J.; Brunner, N. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Scand. J. Gastroenterol. 2008, 43, 186-191.
37. Holten-Andersen, M.N.; Fenger, C.; Nielsen, H.J.; Rasmussen, A.S.; Christensen, I.J.; Brunner, N.; Kronborg, O. Plasma TIMP-1 in patients with colorectal adenomas: A prospective study. Eur. J. Cancer 2004, 40, 2159-2164.
38. Holten-Andersen, M.; Christensen, I.J.; Nilbert, M.; Bendahl, P.O.; Nielsen, H.J.; Brunner, N.; Fernebro, E. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur. J. Cancer 2004, 40, 64-72.
39. Holten-Andersen, M.N.; Stephens, R.W.; Nielsen, H.J.; Murphy, G.; Christensen, I.J.; Stetler-Stevenson, W.; Brunner, N. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin. Cancer Res. 2000, 6, 4292-4299.
40. Roessler, M.; Rollinger, W.; Mantovani-Endl, L.; Hagmann, M.L.; Palme, S.; Berndt, P.; Engel, A.M.; Pfeffer, M.; Karl, J.; Bodenmuller, H.; Ruschoff, J.; Henkel, T.; Rohr, G.; Rossol, S.; Rosch, W.; Langen, H.; Zolg, W.; Tacke, M. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell Proteomics 2006, 5, 2092-2101.
41. Roessler, M.; Rollinger, W.; Palme, S.; Hagmann, M.L.; Berndt, P.; Engel, A.M.; Schneidinger, B.; Pfeffer, M.; Andres, H.; Karl, J.; Bodenmuller, H.; Ruschoff, J.; Henkel, T.; Rohr, G.; Rossol, S.; Rosch, W.; Langen, H.; Zolg, W.; Tacke, M. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 2005, 11, 6550-6557.
42. Wu, C.C.; Chen, H.C.; Chen, S.J.; Liu, H.P.; Hsieh, Y.Y.; Yu, C.J.; Tang, R.; Hsieh, L.L.; Yu, J.S.; Chang, Y.S. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8, 316-332.
43. Chen, X.; Jorgenson, E.; Cheung, S.T. New tools for functional genomic analysis. Drug. Discov. Today 2009, 14, 754-760.
44. Krichevsky, A.M.; Gabriely, G. miR-21: A small multi-faceted RNA. J. Cell Mol. Med. 2009, 13, 39-53.
45. Akao, Y.; Nakagawa, Y.; Naoe, T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 2007 26, 311-320.
46. Faber, C.; Kirchner, T.; Hlubek, F. The impact of microRNAs on colorectal cancer. Virchows Arch. 2009, 454, 359-367.
47. Yang, L.; Belaguli, N.; Berger, D.H. MicroRNA and colorectal cancer. World J. Surg. 2009, 33, 638-646.
48. Hoshida, Y.; Toffanin, S.; Lachenmayer, A.; Villanueva, A.; Minguez, B.; Llovet, J.M. Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin. Liver Dis. 2010, 30, 35-51.
49. Sorensen, K.D.; Orntoft, T.F. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev. Mol. Diagn. 2010, 10, 49-64.
50. Kan, T.; Meltzer, S.J. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr. Opin. Pharmacol. 2009, 9, 727-732.
51. Novakova, J.; Slaby, O.; Vyzula, R.; Michalek, J. MicroRNA involvement in glioblastoma pathogenesis. Biochem. Biophys. Res. Commun. 2009, 386, 1-5.
52. Izumiya, M.; Okamoto, K.; Tsuchiya, N.; Nakagama, H. Functional screening using a microRNA virus library and microarrays: A new high-throughput assay to identify tumor-suppressive microRNAs. Carcinogenesis 2010, 31, in press.
53. Shi, M.; Guo, N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat. Rev. 2009, 35, 328-334.
54. Ho, L.; Fivecoat, H.; Wang, J.; Pasinetti, G.M. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications. Exp. Gerontol. 2010, 45, 15-22.
55. Tazawa, H.; Tsuchiya, N.; Izumiya, M.; Nakagama, H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA 2007, 104, 15472-15477.
56. Tsuchiya, N.; Ochiai, M.; Nakashima, K.; Ubagai, T.; Sugimura, T.; Nakagama, H. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res. 2007, 67, 9568-9576.
57. Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13421-13426.
58. Earle, J.S.; Luthra, R.; Romans, A.; Abraham, R.; Ensor, J.; Yao, H.; Hamilton, S.R. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn. 2010, 12, in press.
59. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; Mitsudomi, T.; Takahashi, T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64, 3753-3756.
60. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G.A.; Liu, C.G.; Croce, C.M.; Harris, C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189-198.
61. Hu, Z.; Chen, J.; Tian, T.; Zhou, X.; Gu, H.; Xu, L.; Zeng, Y.; Miao, R.; Jin, G.; Ma, H.; Chen, Y.; Shen, H. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 2008, 118, 2600-2608.
62. Yu, S.L.; Chen, H.Y.; Chang, G.C.; Chen, C.Y.; Chen, H.W.; Singh, S.; Cheng, C.L.; Yu, C.J.; Lee, Y.C.; Chen, H.S.; Su, T.J.; Chiang, C.C.; Li, H.N.; Hong, Q.S.; Su, H.Y.; Chen, C.C.; Chen, W.J.; Liu, C.C.; Chan, W.K.; Li, K.C.; Chen, J.J.; Yang, P.C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13, 48-57.
63. Markou, A.; Tsaroucha, E.G.; Kaklamanis, L.; Fotinou, M.; Georgoulias, V.; Lianidou, E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54, 1696-1704.
64. Li, W.; Xie, L.; He, X.; Li, J.; Tu, K.; Wei, L.; Wu, J.; Guo, Y.; Ma, X.; Zhang, P.; Pan, Z.; Hu, X.; Zhao, Y.; Xie, H.; Jiang, G.; Chen, T.; Wang, J.; Zheng, S.; Cheng, J.; Wan, D.; Yang, S.; Li, Y.; Gu, J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 2008, 123, 1616-1622.
65. Yan, L.X.; Huang, X.F.; Shao, Q.; Huang, M.Y.; Deng, L.; Wu, Q.L.; Zeng, Y.X.; Shao, J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14, 2348-2360.
66. Chan, S.H.; Wu, C.W.; Li, A.F.; Chi, C.W.; Lin, W.C. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008, 28, 907-911.
67. Schepeler, T.; Reinert, J.T.; Ostenfeld, M.S.; Christensen, L.L.; Silahtaroglu, A.N.; Dyrskjot, L.; Wiuf, C.; Sorensen, F.J.; Kruhoffer, M.; Laurberg, S.; Kauppinen, S.; Orntoft, T.F.; Andersen, C.L. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008, 68, 6416-6424.
68. Diaz, R.; Silva, J.; Garcia, J.M.; Lorenzo, Y.; Garcia, V.; Pena, C.; Rodriguez, R.; Munoz, C.; Garcia, F.; Bonilla, F.; Dominguez, G. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Gene. Chromosome. Canc. 2008, 47, 794-802.
69. Childs, G.; Fazzari, M.; Kung, G.; Kawachi, N.; Brandwein-Gensler, M.; McLemore, M.; Chen, Q.; Burk, R.D.; Smith, R.V.; Prystowsky, M.B.; Belbin, T.J.; Schlecht, N.F. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174, 736-745.
70. Roldo, C.; Missiaglia, E.; Hagan, J.P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G.A.; Volinia, S.; Liu, C.G.; Scarpa, A.; Croce, C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24, 4677-4684.
71. Marcucci, G.; Radmacher, M.D.; Maharry, K.; Mrozek, K.; Ruppert, A.S.; Paschka, P.; Vukosavljevic, T.; Whitman, S.P.; Baldus, C.D.; Langer, C.; Liu, C.G.; Carroll, A.J.; Powell, B.L.; Garzon, R.; Croce, C.M.; Kolitz, J.E.; Caligiuri, M.A.; Larson, R.A.; Bloomfield, C.D. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358, 1919-1928.
72. Calin, G.A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S.E.; Iorio, M.V.; Visone, R.; Sever, N.I.; Fabbri, M.; Iuliano, R.; Palumbo, T.; Pichiorri, F.; Roldo, C.; Garzon, R.; Sevignani, C.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353, 1793-1801.
73. Lu, L.; Katsaros, D.; de la Longrais, I.A.; Sochirca, O.; Yu, H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007, 67, 10117-10122.
74. Guo, Y.; Chen, Z.; Zhang, L.; Zhou, F.; Shi, S.; Feng, X.; Li, B.; Meng, X.; Ma, X.; Luo, M.; Shao, K.; Li, N.; Qiu, B.; Mitchelson, K.; Cheng, J.; He, J. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008, 68, 26-33.
75. Habermann, J.K.; Roblick, U.J.; Luke, B.T.; Prieto, D.A.; Finlay, W.J.; Podust, V.N.; Roman, J.M.; Oevermann, E.; Schiedeck, T.; Homann, N.; Duchrow, M.; Conrads, T.P.; Veenstra, T.D.; Burt, S.K.; Bruch, H.P.; Auer, G.; Ried, T. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131, 1020-1029; quiz 1284.
76. Albrethsen, J.; Bogebo, R.; Gammeltoft, S.; Olsen, J.; Winther, B.; Raskov, H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer 2005, 5, 8.
77. Melle, C.; Ernst, G.; Schimmel, B.; Bleul, A.; Thieme, H.; Kaufmann, R.; Mothes, H.; Settmacher, U.; Claussen, U.; Halbhuber, K.J.; Von Eggeling, F. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005, 129, 66-73.
78. Lee, H.; Rhee, H.; Kang, H.J.; Kim, H.S.; Min, B.S.; Kim, N.K.; Kim, H. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am. J. Clin. Pathol. 2008, 129, 772-779.
79. Mroczko, B.; Groblewska, M.; Wereszczynska-Siemiatkowska, U.; Kedra, B.; Konopko, M.; Szmitkowski, M. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin. Chim. Acta 2006, 371, 143-147.
80. Mroczko, B.; Groblewska, M.; Wereszczynska-Siemiatkowska, U.; Okulczyk, B.; Kedra, B.; Laszewicz, W.; Dabrowski, A.; Szmitkowski, M. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin. Chim. Acta 2007, 380, 208-212.
81. Soroush, A.R.; Zadeh, H.M.; Moemeni, M.; Shakiba, B.; Elmi, S. Plasma prolactin in patients with colorectal cancer. BMC Cancer 2004, 4, 97.
82. Schneider, J.; Bitterlich, N.; Schulze, G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res. 2005, 25, 1507-1515.
83. Zhang, B.; Chen, J.Y.; Chen, D.D.; Wang, G.B.; Shen, P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J. Gastroenterol. 2004, 10, 1643-1646.
84. Zhu, J.; Yao, X. Use of DNA methylation for cancer detection and molecular classification. J. Biochem. Mol. Biol. 2007, 40, 135-141.
85. Tost, J. DNA methylation: An introduction to the biology and the disease-associated changes of a promising biomarker. Methods Mol. Biol. 2009, 507, 3-20.
86. Lofton-Day, C.; Model, F.; Devos, T.; Tetzner, R.; Distler, J.; Schuster, M.; Song, X.; Lesche, R.; Liebenberg, V.; Ebert, M.; Molnar, B.; Grutzmann, R.; Pilarsky, C.; Sledziewski, A. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54, 414-423.
87. Han, M.; Liew, C.T.; Zhang, H.W.; Chao, S.; Zheng, R.; Yip, K.T.; Song, Z.Y.; Li, H.M.; Geng, X.P.; Zhu, L.X.; Lin, J.J.; Marshall, K.W.; Liew, C.C. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res. 2008, 14, 455-460.
88. Brunagel, G.; Vietmeier, B.N.; Bauer, A.J.; Schoen, R.E.; Getzenberg, R.H. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res. 2002, 62, 2437-2442.
89. Leman, E.S.; Schoen, R.E.; Magheli, A.; Sokoll, L.J.; Chan, D.W.; Getzenberg, R.H. Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin. Cancer Res. 2008, 14, 1349-1354.
90. Hurst, N.G.; Stocken, D.D.; Wilson, S.; Keh, C.; Wakelam, M.J.; Ismail, T. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br. J. Cancer 2007, 97, 971-977.
91. Maurel, J.; Nadal, C.; Garcia-Albeniz, X.; Gallego, R.; Carcereny, E.; Almendro, V.; Marmol, M.; Gallardo, E.; Maria Auge, J.; Longaron, R.; Martinez-Fernandez, A.; Molina, R.; Castells, A.; Gascon, P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int. J. Cancer 2007, 121, 1066-1071.
92. Saito, N.; Kameoka, S. Serum laminin is an independent prognostic factor in colorectal cancer. Int. J. Colorectal. Dis. 2005, 20, 238-244.
93. Jain, K.K. Cancer biomarkers: Current issues and future directions. Curr. Opin. Mol. Ther. 2007, 9, 563-571.